Critical Issues in Head and Neck Oncology

Prof. Jan B. Vermorken, MD, PhD, started his medical training in 1961, graduated in 1970 from the University of Amsterdam, the Netherlands, and became a board-certified specialist in internal medicine in 1975. Since that time he has worked in the field of Medical Oncology and was officially registered as a Medical Oncologist in the Netherlands in 1992. He received his PhD in Medical Sciences in 1986 from the Vrije Universiteit in Amsterdam. From May 1997 until October 1, 2009, he was appointed Professor of Oncology at the University of Antwerp (UA), in Antwerp, Belgium and head of the Department of Medical Oncology at the University Hospital Antwerp (UZA), in Edegem, Belgium. After his retirement he remained connected to both University (Emeritus Professor) and University Hospital (consultant). His main fields of interest are head and neck oncology and gynecologic oncology. He chaired both the Head and Neck Cancer Group (2006-2009) and the Gynecologic Cancer Group (1983-1989) of the European Organization for the Research and Treatment of Cancer (EORTC). He was founding chair of the Gynecologic Cancer InterGroup (GCIG: 1997-2003) and strongly involved in establishing the Head and Neck Cancer International Group (HNCIG) in 2015. Professor Vermorken is member of various scientific societies, member of several editorial boards of International journals, reviewer of multiple cancer journals and author or co-author of more than 700 publications. He was Editor-in-Chief of Annals of Oncology from 2009 to 2014 and is chief editor of the head and neck cancer section of The Oncologist (since 2003), and the head and neck section of Frontiers in Oncology (since 2015), is editorial chair of ONCOhemato (multidisciplinary journal; since 2007) in Belgium and chaired Oncotherapie (an internet platform) in The Netherlands (2007-2020). He received the ESMO award in 2007 and on March 1, 2013 he received the title of Commander in the Order of Leopold for his contributions to oncology. Prof. Volker Budach, MD, is Head of the Departments of Radiation Oncology at the Charité University Medicine Berlin. He became a board-certified radiologist in 1985 and radiation oncologist in 1988 at the University of Essen and was appointed as full professor and chair of the Department for Radiation Oncology at the Charité University Clinics, Campus-Mitte in 1993. He was the founder and the head of the Tumor center Berlin (1994-2011). He was a board member and treasurer of the European Society for Radiotherapy and Oncology (ESTRO) from 1996 till 2004 and chairman of the EORTC Radiation Oncology Group (ROG) from 2000 till 2003, followed by an “executive board” membership of the EORTC and chairman of the "Clinical Research Division" of the EORTC (2003-2006). He was a board member and president of the German Society for Radiation Oncology (DEGRO) from 2005 till 2011. He was a founding member and chair of the German Cooperative Interdisciplinary soft tissue sarcoma group (IAWS)(2006-2012) and a founding and board member of the German Interdisciplinary Head and Neck Group (2008-2019) of the German Cancer Society (DKG). He was additionally appointed as chair of the Department for Radiation Oncology at the Charité-University Medicine Berlin, Campus-Virchow in 2006, and also appointed as chair of the department of Radiation Oncology at the Campus Benjamin-Franklin in 2014. He was a member of the German interdisciplinary Guideline Commissions on Diagnosis, Treatment and Follow-up for breast cancer (2015 until now) and anal cancer (2019-2020). He is a member of many international oncologic societies (e.g. ASCO, ASTRO, ESTRO) and Principle Investigator of several studies in head and neck cancer. He received in 2022 the ESTRO Lifetime Achievement Award and the DEGRO Medal as a founding member of the German Society for Radiation Oncology. He was an author or co-author in 396 publications (PubMed, 10/22). Professor C. René Leemans, MD, PhD is chair of the Department of Otolaryngology Head and Neck Surgery at the Amsterdam University Medical Centres, VUmc, Amsterdam. He is Director of the Advanced Fellowship Program in Head and Neck Surgery and Oncology at the VU University Medical Centre Amsterdam. His special interests include head and neck oncology, reconstructive and microvascular surgery, and basic research. René Leemans has made a sustained and internationally recognized contribution to cancer care and research in the field of head and neck oncology over the past decades. His scientific standing has been recognized by election as President of the Netherlands Society of Otolaryngology-Head and Neck Surgery, and the Dutch and European Head and Neck Societies. He also serves on the Leadership of the American Head and Neck Society (AHNS). He (co-)authored more than 400 papers and book chapters on head and neck oncology and is regularly invited to speak at international conferences and tutor at courses. He leads the successful Make Sense Awareness Campaign. Professor Jean-Pascal Machiels MD, PhD, is head of department of medical oncology and director of the Institut Roi Albert II Cancer centre, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels Belgium. He trained at Université Catholique de Louvain, Brussels, Belgium, where he gained his MD in 1993 and his PhD in 2001 and at Johns Hopkins School of Medicine, Baltimore USA, where he was a Fellow in Medical Oncology from 1998 until 2000. His main interests include Head and Neck cancer, and phase 1 clinical trials. He has published more than two hundred papers reporting on clinical trials and translational research Professor Piero Nicolai, MD, is Head of the Section of Otorhinolaryngology – Head and Neck Surgery, Department of Neurosciences, at the Azienda Ospedale Università di Padova and Professsor of Otorhinolaryngology at the University of Padova. From 2006 to 2019 he has served as Professor and Chairman of the Unit of Otorhinolaryngology – Head and Neck Surgery at ASST Spedali Civili Brescia - University of Brescia. He received his MD degree at the University of Padova, where he completed his residency program in Otorhinolaryngology and subsequently in Oncology. His clinical and research activities are mainly focused on head and neck oncology and endoscopic sinus and skull base surgery. Prof. Nicolai has authored or co-authored 389 papers in peer-reviewed journals as well as 61 book chapters. He has been co-editor of 6 books, and Editor of 6 issues of Current Opinion in Otolaryngology & Head and Neck Surgery on Head and Neck Oncology. He is a member of the editorial board of the journals Annals of Otology, Rhinology & Laryngology, Head and Neck, International Journal of Head & Neck Surgery, The Laryngoscope, and Associate Editor of Frontiers in Oncology – Head and Neck Cancer Section. Professor Brian O’Sullivan, MD, is the inaugural Bartley-Smith/Wharton Chair (Emeritus) in Radiation Oncology and immediate past Chair of the Head and Neck Program at the Princess Margaret Cancer Centre, University of Toronto. He has Co-chaired the Head and Neck Steering committee of the US National Cancer Institute and is Editor-in Chief of the UICC Manual of Clinical Oncology, Chair of the UICC Prognostic Factors Classification Committee, Chair of the UICC Head and Neck Committee, and co-editor of the UICC TNM Classification of Malignant Tumours and Liaison to the AJCC Expert Committee on Head and Neck Cancer. He is also a recognized expert in the management of sarcoma and a past-President of the Connective Tissue Oncology Society (CTOS). He has published more than 700 manuscripts more than 460 of which are peer-reviewed. Professor O’Sullivan has received some of the top awards in radiation oncology including the Juan A del Regato Gold Medal, the award of Honor of the Radiological Society of North America, and the American Society of Radiation Oncology (ASTRO) Gold Medal.

The gut microbiota and anticancer immunotherapy, Laurence Zitvogel.- The bidirectional communication between tumor cells and other components of the tumor microenvironment, Phil Sloan.- Resistance mechanisms in immune checkpoint inhibitors and radiotherapy and how to overcome this, Kirsten Lauber.- DNA repair mechanisms as a new target in head and neck cancer, Kevin Harrington.- How to standardize molecular profiling programs for routine patient care, Ingeborg Tinhofer.- Novel immune oncology targets beyond PD-1/PD-L1 in head and neck cancer, Christophe Le Tourneau.- Analytic methods to understand head and neck cancer evolution to guide therapeutic approaches, Ben O'Leary.- Clinical cases, Jean Pascal Machiels.- Updates from the European Head & Neck Society (EHNS), Wojciech Golusinski (President of EHNS)Section 2:  Primary disease Piero Nicolai.- Sensitivity and specificity of extranodal extension in SCCHN: unlocking the strongest prognostic factor in head and neckcancer, Brian O'Sullivan.- From photon to proton: what's in it for head and neck cancer patients?, Volker Budach.- Lessons learned from RTOG 1016 and DE-ESCALaTE: what's next?, Hisham Mehanna.-Treatment intensification in LA-SCCHN: what are the options and for who?, Jan Vermorken.- Immune checkpoint inhibitors in the curative setting: preclinical and clinical data, Jean-Pascal Machiels.- Carcinoma of unknown primary: diagnostics and the potential of transoral surgery, René Leemans.- Clinical cases, Volker Budach.- Individualized therapy in 1-line R/M-SCCHN: what selection criteria should we use?, Petr Szturz.- Patterns of response to immune oncology drugs: how relevant are they in SCCHN?, Amanda Psyrri.- The role of radiotherapy in oligometastatic or oligoprogressive disease in R/M-SCCHN, Daan Nevens.- Updates from the EORTC Head and Neck Cancer Group (HNCG), Jean-Pascal Machiels (Chair of EORTC-HNCG).- Real world evidence in head and neck cancer, Anil D'Cruz (UICC president.- Pathology driven treatment of skull base tumors, Piero Nicolai.- Modern day reconstruction of facial bones, Sat Parmar.- Targeting molecular/minimal residual disease using novel technologies and clinical trials design, Lillian Siu.- New developments in surgery for malignant salivary gland tumors, Jeroen Meulemans.- New systemic therapies in salivary gland cancer, Ethan Argiris. Exercise and nutrition interventions in head and neck cancer, Paolo Bossi.- Telehealth intervention in head and neck cancer patients: a promise?, Irma Verdonck-de Leeuw.

"The authors advocate a need to increase the education and knowledge of physicians about the positive effects associated with correct nutritional interventions and physical exercise and to advise patients of this strategy benefit. This publication, like the previous volumes, is 'essential reading' for all professional staff of a head and neck cancer multidisciplinary team, as well as any "budding physicians" that aspire to join a head and neck cancer team." (P J Bradley, The Journal of Laryngology & Otology, March 28, 2023)

“The authors advocate a need to increase the education and knowledge of physicians about the positive effects associated with correct nutritional interventions and physical exercise and to advise patients of this strategy benefit. This publication, like the previous volumes, is ‘essential reading’ for all professional staff of a head and neck cancer multidisciplinary team, as well as any “budding physicians” that aspire to join a head and neck cancer team.” (P J Bradley, The Journal of Laryngology & Otology, March 28, 2023)